This inventor holds 9 USPTO granted patents and 7 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignees: Medimmune Limited, University of Georgia Research Foundation Inc. Active years: 2016-2025.
Company Filing History:
10 out of 546 
1 out of 870 Years Active: 2016-2025
Title: The Innovative Contributions of Antonio Digiandomenico
Introduction
Antonio Digiandomenico is a notable inventor based in Gaithersburg, MD (US). He has made significant contributions to the field of biomedical research, particularly in the development of therapies targeting Pseudomonas infections. With a total of nine patents to his name, Digiandomenico's work has the potential to impact the treatment of serious infections.
Latest Patents
Among his latest patents is a groundbreaking disclosure on combination therapies using anti-Pseudomonas PSL and PCRV binding molecules. This patent relates to therapies that utilize these binding molecules for the prevention and treatment of infections. Another significant patent involves polynucleotides encoding antibodies or antigen binding fragments that bind to PcrV. This disclosure includes vectors and host cells that comprise these polynucleotides, further advancing the field of targeted therapies.
Career Highlights
Digiandomenico has worked with prominent organizations such as MedImmune Limited and the University of Georgia Research Foundation, Inc. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to innovative research.
Collaborations
Some of his notable coworkers include Charles K. Stover and Paul Warrener. Their collaborative efforts have likely enhanced the quality and impact of Digiandomenico's research.
Conclusion
Antonio Digiandomenico's contributions to the field of biomedical research through his patents and collaborations highlight his role as an influential inventor. His work continues to pave the way for advancements in the treatment of Pseudomonas infections.